|
Common name |
B-hCD39 MC38 | Catalog number | 311521 |
| Aliases | ENTPD1 | Disease | Colon carcinoma |
|
Organism |
Mouse |
Strain | C57BL/6 |
| Tissue types | Colon | Tissue | Colon |
Human CD39 is highly expressed on the surface of B-hCD39 MC38 cells.
Application
Protein expression analysis
CD39 and EGFP expression analysis in B-hCD39 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD39 MC38 cultures were stained with species-specific anti-CD39 antibody. Human CD39 was detected on the surface of B-hCD39 MC38 cells but not wild-type MC38 cells. EGFP was detected in B-hCD39 MC38 cells but not wild-type MC38 cells. The 1-F07 clone of B-hCD39 MC38 cells was used for in vivo experiments.
Tumor growth curve & Body weight changes
Subcutaneous homograft tumor growth of B-hCD39 MC38 cells. B-hCD39 MC38 cells (5x105) and wild-type MC38 cells (5x105) were subcutaneously implanted into B-hCD39 mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCD39 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
Protein expression analysis of tumor cells
B-hCD39 MC38 cells were subcutaneously transplanted into B-hCD39 mice (n=6). At the end of the experiment, tumor cells were harvested and assessed for human CD39 expression by flow cytometry. As shown, human CD39 was highly expressed on the surface of tumor cells. Therefore, B-hCD39 MC38 cells can be used for in vivo efficacy studies of novel CD39 therapeutics.
Tumor growth curve & Body weight changes
Protein expression analysis of tumor cells
B-hCD39 MC38 cells were subcutaneously transplanted into B-hPD-1/hCD39 mice (n=5). At the end of the experiment, tumor cells were harvested and assessed for human CD39 expression by flow cytometry. As shown, human CD39 was highly expressed on the surface of tumor cells. Therefore, B-hCD39 MC38 cells can be used for in vivo efficacy studies of novel CD39 therapeutics.
